SIRPB1 regulates inflammatory factor expression in the glioma microenvironment via SYK: functional and bioinformatics insights

Background SIRPB1 expression is upregulated in various tumor types, including gliomas, and is known to contribute to tumor progression; nevertheless, its function in the immune milieu of gliomas is still mainly unknown. Methods This study, we analyzed 1152 normal samples from the GTEx database and 670 glioma samples from the TCGA database to investigate the relationship between the expression of SIRPB1 and clinicopathological features. Moreover, SIRPB1 gene knockout THP-1 cell lines were constructed using CRISPR/Cas9 and were induced into a co-culture of macrophages and glioma cells in vitro to learn more about the role of SIRPB1 in the glioma immune milieu. Lastly, we established a prognostic model to predict the effect of SIRPB1 on prognosis. Results Significantly higher levels of SIRPB1 expression were found in gliomas, which had an adverse effect on the immune milieu and correlated poorly with patient survival. SIRPB1 activation with certain antibodies results in SYK phosphorylation and the subsequent activation of calcium, MAPK, and NF-κB signaling pathways. This phenomenon is primarily observed in myeloid-derived cells as opposed to glioma cells. In vitro co-culture demonstrated that macrophages with SIRPB1 knockout showed decreased IL1RA, CCL2, and IL-8, which were recovered upon ectopic expression of SIRPB1 but reduced again following treatment with SYK inhibitor GS9973. Critically, a lower overall survival rate was linked to increased SIRPB1 expression. Making use of SIRPB1 expression along with additional clinicopathological variables, we established a nomogram that showed a high degree of prediction accuracy. Conclusions Our study demonstrates that glioma cells can be activated by macrophages via SIRPB1, subsequently reprogramming the TME, suggesting that SIRPB1 could serve as a promising therapeutic target for gliomas. Supplementary Information The online version contains supplementary material available at 10.1186/s12967-024-05149-z.


Background
Gliomas provide a serious challenge to neuro-oncology because of their aggressive nature and dismal prognosis, which are characteristics of their high malignancy [1].Gliomas have an especially complex immune microenvironment, which is made up of many immune cells and pro-tumorigenic cytokines that aid in the development of tumors and immune evasion [2].Although the brain has been proven to be privileged to a certain extent, subsequent studies have shown that the brain does not completely rule out immune cells from peripheral blood [3].The majority of the immune subset in glioblastoma is made up of myeloid-derived cells, which include neutrophils, dendritic cells (DC), microglia, tumor-associated macrophages (TAM), and bone marrow-derived suppressor cells (MDSC).TAM secretes chemokines and substances that promote the growth and survival of tumor cells, making up the majority of the non-tumor cells in gliomas [4,5].
Signal Regulatory Protein Beta 1 (SIRPB1) is a notable molecule within this complex environment.SIRPB1, a cell surface glycoprotein, is mainly expressed in monocytes and dendritic cells.It is a member of the immunoglobulin superfamily as well as the signal regulatory protein family [6,7].Some studies indicate that DAP12 expression is crucial for surface presentation of SIRPB1 [8].Although SIRPB1's functions were initially identified outside of oncological settings, new research highlights the critical role it plays in the glioma immunological landscape, especially when it comes to spleen tyrosine kinase (SYK) [9].SYK significantly impacts the tumor microenvironment and antitumor immunity efficacy [10], influencing glioma progression by altering cell proliferation and migration pathways [11].Our knowledge of the significance of SIRPB1 and SYK signaling in cancer biology has significantly changed as a result of this interaction's recognition as being important in glioma immune response modulation.
We attempt to analyze the role of SIRPB1 in the glioma immune microenvironment in detail and determine its activation and related pathways, the release of tumorpromoting cytokines, and its role in prognosis, which provides a basis for further exploration of SIRPB1 as a potential therapeutic target, given the complexity and importance of the glioma immune microenvironment and the incomplete understanding of its mechanism.

RNA sequencing and clinic information from TCGA and GTEx data repository
TCGA and GTEx expression data processed by the TOIL process [12] were obtained from XENA [13].The prognostic data were obtained from the study of Liu et al. [14].The clinical data, including WHO grade, IDH mutation status, and 1p/19q co-deletion status, were sourced from the study by Ceccarelli et al. [15].Samples from GBM and LGG cohorts were included in the analysis of TCGA glioma samples.Missing data were noted, and tumor samples were categorized into high or low SIRPB1 expression groups based on median levels.Our study followed ethical guidelines, including patient consent, and complied with Xena, TCGA and GTEx publication standards.

Differentially expressed genes (DEGs) analysis
The package DESeq2 was utilized for the analysis of differential gene expression [16].Criteria for significant gene identification included an absolute log 2 fold change > 1.5 and an adjusted P < 0.01.Results will be visualized through Volcano plots and heatmaps.We further used Toil-processed RNAseq data in TPM format from TCGA and GTEx to compare SIRPB1 expression across 33 tumor types [12].

Enrichment analysis
For enrichment analysis, we employed the R package ClusterProfiler [17] to conduct gene ontology (GO) enrichment analysis, covering biological process (BP), cellular components (CC), and molecular function (MF) categories [18,19].We also performed the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis [20][21][22].A false discovery rate (FDR) threshold of < 0.05 was used to identify significant GO functions and KEGG pathways.

Immune infiltration analysis and immunological constant of rejection (ICR) analysis
We used the ssGSEA approach with the package GSVA to assess the infiltration of 24 immune cell types in malignancies [23].This list includes macrophages, mast cells, neutrophils, eosinophils, various NK and DC subsets, multiple T cell types, and B cells.Using hallmark gene expression profiles for these cells, we calculated relative enrichment scores for each cell type in individual samples.
To identify the cell types most closely linked with SIRPB1, we consulted two single-cell sequencing datasets: one focused on astrocytoma [24] and another on glioblastoma [25].SIRPB1 expression across different cell types was analyzed using the Single Cell Portal.

Single-cell data analysis and pseudotime analysis
We used the GSE117891 dataset [34] for single-cell analysis.Cells were annotated and clustered by type.Microglial and macrophage cells were then sorted into high and low IL1RN expression groups for GO, KEGG, and GSEA analyses.The Monocle2 and Monocle3 algorithms were used to do a pseudotime analysis of IL1RN [35][36][37].

Statistical analysis
For data analysis, we employed R software (version 3.6.2).Image analysis was done via Fiji, while GraphPad Prism 8.0 was used for quantitative assessments.Statistical comparisons were made using the Student's t-test and the Wilcoxon test.For multiple-group comparisons, we used analysis of variance.Survival analysis was executed using the Kaplan-Meier curve's log-rank test via the survminer package (ver0.4.8, https:// cran.r-project.org/ web/ packa ges/ survm iner/ index.html).

Construction and evaluation of the nomogram
To identify survival-related factors, we integrated SIRPB1 expression and key clinicopathological variables into a multivariate COX regression-based nomogram.Utilizing the R package rms (ver.5.1-4, https:// cran.r-project.org/ web/ packa ges/ rms/ index.html), we generated nomograms and calibration plots to calculate patient scores.The C-index was used to assess how accurate the nomogram was at making predictions.

Immunohistochemical staining and immunofluorescence
In summary, paraffin slides from glioma patients were obtained from the First Hospital of Jilin University's Pathology Department.Slides underwent dewaxing, antigen retrieval, and peroxidase blocking.After BSA blocking, primary and secondary antibodies (detailed in Additional file 1: Table S1) were applied sequentially, followed by DAB chromogenic solution for immunohistochemistry or TSA for multicolor immunofluorescence.Slides were then stained with DAPI, treated for autofluorescence, and scanned.
For lentivirus production, 80%-confluent HEK293T cells in 10cm dishes were switched to OPTI-MEM.Following TransEXP guidelines, we mixed pMD2.G (4 μg), psPAX2.0(8 μg), and target plasmids (12 μg) in 1.5 ml OPTI-MEM, which was combined with another 1.5 ml OPTI-MEM containing 60 μl of transfection reagents.After a 20 min incubation, the mixture was added to the dish.Culture supernatant was collected at 48 and 72 h, filtered through a 0.45 μm PES filter, and concentrated using 5 × PEG8000.After overnight storage at 4 ℃, it was centrifuged at 4 ℃ and 4000 × g for 20 min.The supernatant was discarded, and the lentivirus was resuspended in a serum-free medium.

Construction of SIRPB1 knockout THP-1 cell lines
THP-1 cells were infected by SIRPB1-WT/KO lentivirus with 8 μg/ml polybrene.After 48 h, 5 μg/ml puromycin was added.Post-7-d culture, T7E1 digestion confirmed gene editing using a Genome-Editing Mutation Detection Kit (Beyotime).Cells were then diluted to 2 cells/ml and cultured in 96-well plates for 21 day.Genomic DNA was extracted using the Animal Tissue DNA Isolation Kit (FOREGENE) and verified via PCR with specific primers.Sanger sequencing at Sangon Biotech identified base deletions.

Protein extraction and western blot
In this study, nuclear and cytoplasmic proteins were separated using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime).For total protein, cells were treated with 5 ug/ml Brefeldin A (Beyotime) for 4 h and lysed with RIPA lysate (Beyotime) containing protease and phosphorylase inhibitors (targetmol).SDS-PAGE gel electrophoresis was performed as needed, using gels of varying concentrations (6, 8, 10, 12, 15% from Sangon Biotech.), and specific antibodies (detailed in Additional file 1: Table S1) were applied.

Co-immunoprecipitation (Co-IP)
After discarding the culture medium, cells were lysed on ice using IP lysate (Beyotime) containing protease inhibitors.The protein extract was incubated overnight at 4 ℃ with either mouse IgG or FLAG antibody.Protein A/G beads (Abmart) were added and incubated at 4 ℃ for 6 h, followed by elution with 1 × loading buffer.

Cellular calcium detection
For calcium assays, THP-1 cells induced into macrophages were loaded with a Fluo-4 calcium probe using a Fluo-4 Calcium Assay Kit (Beyotime).Cells were then exposed to U87 cell culture supernatant and imaged every 5 s under a fluorescence microscope.Images were analyzed by FIJI software.

Real-time quantitative PCR (RT-qPCR)
Total RNA was extracted using TRIGene (Genstar).1 μg of RNA was reverse transcript using the RT Easy II kit (Foregene).qPCR was performed using SYBR Green Master Mix (Yeasen), with GAPDH as the reference gene.Primer sequences are in Additional file 1: Table S2.

Luminex multi-cytokines detection
For co-culture experiments, U87 cells were placed in a transwell chamber above THP-1-induced macrophages in a 6-well plate.After 48 h, culture media from both layers were collected, filtered through a 0.45 μm filter, and stored at -80 ℃.Luminex assays were conducted by Labex (Shanghai).Data were analyzed post-standardization per million THP-1 macrophages.

Clinical characteristics
In this study, we analyzed 670 RNA-seq datasets with clinical data from TCGA LGG and GBM projects (Table 1).The cohort consisted of 386 males and 284 females, median age of 46.The data included 216 WHO-II, 237 WHO-III, and 160 WHO-IV grade cases.IDH mutations were present in 424 patients (64.1%) and 1p/19q co-deletion in 168 (25.3%).SIRPB1 expression correlated significantly with WHO grade, IDH status, 1p/19q co-deletion, primary therapy outcome, histological type, and age (all P < 0.001) but not with race, PIK3CA status, EGFR status, and gender.

Differential expression of SIRPB1
We compared the expression of SIRPB1 in normal GTEx samples with 33 TCGA cancer types using the Wilcoxon test (Fig. 1A).Elevated SIRPB1 levels were observed in several cancers, including GBM and LGG, while decreased levels were found in cancers like LUAD and PRAD (all P < 0.001).The high expression of SIRPB1 is associated with poor prognosis in glioma and kidney renal clear cell carcinoma, but it seems to be a protective factor in skin cutaneous melanoma (Fig. 1B).Kaplan-Meier curves in Fig. 1C show that higher SIRPB1 expression is linked to poorer Overall Survival (OS) and Progression-Free Interval (PFI) in gliomas.SIRPB1 was notably high in glioma samples (P < 0.001, Fig. 1D).The ROC curve suggested SIRPB1's potential as a diagnostic marker (AUC = 0.674, Fig. 1E).In the areas where glioma cells gathered, SIRPB1 staining increased with the increase of glioma grade (Fig. 1F, G).Through the   Fig. 1 (See legend on previous page.) follow-up of 70 patients with different grades of gliomas in this study center, we found that the expression of SIRPB1 was associated with poor prognosis (Fig. 1H).In the fresh glioma tissue samples we collected, the expression of SIRPB1 detected by Western blot was significantly higher than that in paracancerous tissues (Fig. 1I, Additional file 1: Figure S1A).

The correlation between SIPRB1 expression and immune infiltration
We used the Single Cell Portal to evaluate datasets for glioblastoma and astrocytoma in order to identify the cells in gliomas that had high expression of SIRPB1.SIRPB1 was predominantly found in macrophages or microglia, with low expression in tumor cells (Fig. 2A,  B) consistent with our Western blot and immunohistochemical findings.
We used the CCLE database to analyze SIRPB1 expression in monocyte and common glioma cell lines in order to validate our hypothesis.THP-1 monocytes showed significantly higher SIRPB1 levels than glioma cell lines (Fig. 2H).Subsequent cultures of glioma cell lines, macrophages, monocytes, and microglial cells in both humans and mice confirmed that SIRPB1 is primarily expressed in macrophages and monocytes (Fig. 2I).

DEG identification and functional enrichment analysis of DEGs
In the combined TCGA-GBM and LGG datasets, 387 DEGs were identified between high and low SIRPB1 expression samples, based on cut-off criteria of adjust P < 0.01 and |log2FC|> 1.5, including 352 up-regulated and 35 down-regulated genes (Additional file 1: Table S3).These DEGs are visualized in a volcano plot (Fig. 3A).
We performed GO and KEGG enrichment analysis on the 387 DEGs to investigate the functional role of SIRPB1 in glioblastoma.A total of 703 significant terms were enriched (Additional file 1: Table S4).According to z-score enrichment results, SIRPB1 is likely involved in cytokine-mediated signaling, cell chemotaxis, and leukocyte migration.The DEGs primarily relate to the external side of the plasma membrane and receptor-ligand activity (Fig. 3B).The enrichment analysis suggests that these DEGs are mainly associated with immune response.

SIRPB1-related signaling pathways based on GSEA
We used GSEA on low-and high-SIRPB1 samples to identify pathways that are differentially active in gliomas.Significant differences were found in the TYROBP causal network in microglia, IL10 signaling, and cytokinecytokine receptor interaction (|NES|> 1, adjust P < 0.05, FDR q < 0.25, Fig. 3C).
To assess the impact of SIRPB1 knockout on THP-1 cell polarization, we examined STAT1 and STAT6 phosphorylation in M1 and M2 polarizations.No significant changes were observed in the SIRPB1 KO  T 9 8 G T   S1B).qPCR revealed that SIRPB1 knockout reduced the transcription levels of IL1B (only for KO#2), TNF, and IL10 but didn't affect IL6 and TGFB1.Notably, SIRPB1 knockout significantly downregulated IL-8 and CCL2 in M1 and IL1RA in M2 polarization (Fig. 4E).

Investigating the effect of SIRPB1 on IL1RA expression at the single-cell level
We examined a single-cell dataset (GSE117891) that was centered on macrophages and microglia in order to clarify the signaling pathways associated with SIRPB1.We identified 8 cell clusters based on marker genes (Fig. 5A).IL1RN and CXCL8 were highly expressed in neutrophils, while CCL2 was predominant in macrophages-microglia (Fig. 5B and Additional file 1: Figure S2A).In these cells, high IL1RN expression was associated with processes like tumor necrosis factor response and cell chemotaxis (Fig. 5C).KEGG analysis revealed enrichment in pathways like phagosome and TNF signaling (Additional file 1: Table S5).Monocle pseudotime showed a developmental trajectory of increasing IL1RN expression (Fig. 5D-I).

Co-culturing U87 with macrophages reveals that SIRPB1 can influence the immune microenvironment of gliomas
We set up a co-culture system (Fig. 6A) and collected a conditioned medium after 48 h.The medium revealed elevated VEGF, PDGF-BB, IL-8, and G-CSF levels in the upper chamber (U87MG) and higher CCL2, IL1B, and CCL5 levels in the lower chamber (macrophages).SIRPB1 KO had lower inflammatory factors than SIRPB1 WT (Fig. 6B).Specifically, IL-8 and IL1RA were significantly lower in the SIRPB1 KO group (Fig. 6C).After 48 h of HUVEC conditioning, CXCL10 levels surged, but the increase was less pronounced in the SIRPB1 KO group  (Fig. 6D).We investigated the function of SIRPB1 in calcium signaling and discovered that it mostly affects earlystage calcium signaling, having little effect on the peak but delaying the beginning (Fig. 6E, F).

Phosphorylation of SYK is necessary for SIRPB1 to reshape immune microenvironment
We detected that SIRPB1 binds to SYK through DAP12 adaptor protein in macrophages by  co-immunoprecipitation (Fig. 7A).Anti-FLAG antibody was used to activate SIRPB1 to up-regulate the expression of CCL2, IL-8 and IL1RA (Fig. 7B, Additional file 1: Figure S1E), which could be blocked by SYK inhibitor GS-9973 (Fig. 7C, Additional file 1: Figure S1F), confirming that SYK was involved.Furthermore, we found that there was a constitutive phosphorylation of SYK in the co-culture experiment.The level of SYK phosphorylation in SIRPB1 KO was lower than that in SIRPB1 WT at the early stage of co-culture, indicating that SIRPB1 was partially involved in the phosphorylation of SYK.The absence of SIRPB1 could not completely block the phosphorylation of SYK (Fig. 7D, Additional file 1: Figure S1G).We found that compared with 2 μM GS-9973, 5 μM SC-75741 could only slightly inhibit the expression of CCL2 but had no significant inhibitory effect on the expression of IL1RA and IL-8 (Fig. 7E, Additional file 1: Figure S1H).Blocking SIRPB1 binding (without secondary antibody) did not significantly inhibit these expressions (Fig. 7F, Additional file 1: Figure S1I).Combined with the existing results and literature, we can preliminarily explain the role of SIRPB1 in glioma-associated macrophages (Fig. 7G).

Correlations between SIRPB1 expression and clinical characteristics in glioma patients
Statistical analysis of TCGA data showed significant correlations between SIRPB1 expression and clinical parameters like WHO grade, IDH status, and 1p/19q codeletion (Fig. 8A, all P < 0.001).Additionally, a poor prognosis was predicted by the expression level of SIRPB1 in the LGG cohort, while this was not the case for the GBM group (Fig. 8B).Logistic regression analysis further confirmed SIRPB1's significant association with WHO grade, IDH status, 1p/19q co-deletion, primary therapy outcome, and EGFR status in glioma samples (Table 2).

Construction of a prognostic model incorporating SIRPB1 and clinicopathological features
Table 3 details univariate and multivariate Cox regression analyses for OS.The multivariate model contained variables that were significant in the univariate analysis (P < 0.05).These included WHO grade, IDH status, 1p/19q co-deletion, primary therapy outcome, age, EGFR status, and SIRPB1 expression (all P < 0.001).Multivariate analysis identified IDH status, primary therapy outcome, age, and SIRPB1 expression as independent OS prognostic factors.Nomograms for OS and PFI were developed based on multivariate findings, displayed in Fig. 8C and  D. The Concordance Index (C-index) for OS is 0.831 and for PFI is 0.738.Calibration plots in Fig. 8E validate the model's accuracy in predicting 1-, 3-, and 5-year survival rates, with bias-corrected lines closely aligning with the ideal line.We validated the prognostic model with the prognostic information of patients followed up by our medical institution and the level of SIRPB1 expression in IHC sections of patients and confirmed the effectiveness of this prognostic model again (Fig. 8F).

The role of high SIRPB1 expression in different subgroups of clinicopathological characteristics
The forest plot in Fig. 8G highlights SIRPB1's prognostic impact across TCGA subgroups.Specifically, SIRPB1 was significant in WHO-II&III (HR: 2.304, P < 0.001), non-codel 1p/19q co-deletion (HR: 2.531, P < 0.001), and IDH wildtype (HR: 2.123, P < 0.001) subgroups.Elevated SIRPB1 levels correlated with worse OS and PFI in these specific patient categories, as shown in Fig. 8H and Additional file 1: Figure S2C, emphasizing the SIRPB1's role in affecting the prognosis of glioma patients with varied pathological features.

Discussion
Signal Regulatory Proteins (SIRPs) are immunoglobulin superfamily members with three main subtypes: SIRPα, SIRPβ, and SIRPγ [38,39].SIRPβ causes tyrosine phosphorylation through DAP12 or DAP10 adaptors even though it lacks a tyrosine-based signaling unit [6,8].Prior work by Song et al. [40] linked SIRPB1 to tumor growth in prostate cancer via the AKT pathway.
Considering the predominant expression of the SIRP family in neurons and myeloid cells [41] and the high frequency of TAMs in gliomas [5], Our attention was drawn to SIRPB1's function in TAMs.Using TCGA data, single-cell portal, and TIMER databases, we found a strong correlation between SIRPB1 and macrophages.Consistent with the notion that glioma-associated macrophages exhibit both M1 and M2 features, further cell line analyses and immunofluorescence staining verified SIRPB1 expression in monocytes and macrophages [42].
Numerous cells release a variety of mediators in the glioblastoma multiforme (GBM) microenvironment, such as chemokines and cytokines [43,44].These molecules activate G-protein-coupled receptors, influencing cell migration and gene expression [45,46].Chemokines and their receptors are pivotal in cancer growth and immune cell interactions [47,48].Our research connects SIRPB1 to important chemokines, cytokines, and immunological markers using GSEA and PPI network design, indicating its function in regulating immune-related pathways.
The JAK/STAT pathway is essential for various cellular functions, including immune responses and inflammation [49].JAK is activated by extracellular chemicals, phosphorylating STAT proteins, which in turn alter the nucleus's gene expression patterns [50].This pathway  regulates macrophage phenotype and activation.For example, interferon-γ increases inflammation and microbial death by activating STAT1 [51], while IL-4 and IL-13 activate STAT6, which is crucial for M2a macrophage polarization [52].We looked into how macrophage polarization markers and STAT phosphorylation were affected by SIRPB1 deletion.While most classic markers remained stable, TNFα and IL10 levels decreased in the SIRPB1 KO group, suggesting a nuanced role for SIRPB1 in macrophage function.We propose two potential explanations for this observation.First, one or more of the molecules LPS, IFN-γ, IL-4, and IL-13 may serve as ligands for SIRPB1.However, direct interaction between these compounds and SIRPB1 has not been demonstrated by either endogenous or exogenous CO-IP assay (results not shown).Second, M1, M2, or TAMs may produce secretory factors that act as ligands for SIRPB1 during polarization, thereby activating SIRPB1 through autocrine or paracrine pathways.We intend to investigate this latter possibility in further work by employing CO-IP and protein mass spectrometry techniques to optimize the tag peptide's location and create antibodies with increased affinity and specificity.
Our study of a single-cell dataset using the signaling pathway of the IL1RN gene showed that IL1RN expression in glioma-associated macrophages changes from low to high.TNF, NF-κB, osteoclast differentiation, and SYK pathways may explain these findings [69].We speculate that after SIRPB1 deletion, inadequate early SYK phosphorylation could impact downstream pathways.It will need further investigation to comprehend the intricate interactions between these routes fully.We detected the phosphorylation level of ERK after co-culture, but we found that after about 12 h-24 h, the phosphorylation level of ERK became irregular, and even at 48h, the phosphorylation level of SIRPB1 KO could be higher than that of SIRPB1 WT in some repeated experiments, possibly due to the activation of some feedback mechanism.For example, Zhang et al. [70] found that two transcripts of IL1RN (ENST00000259206.9 and ENST00000361779.7)were generated by mutually exclusive exons, which could inhibit ERK through some negative feedback mechanism.Between macrophages and microglia in vivo and the THP-1 model in vitro, there were variations in their expression profiles.
We have made every effort to investigate the link between the key components of gliomas, including tumor cells, TAM, and blood vessels; however, the true condition in vivo cannot yet be fully restored.In an effort to investigate further SIRPB1 in vivo experimental mechanisms, our team is building SIRPB1 knockout mice.Future studies could explore the potential of SIRPB1 as a therapeutic target through the development of specific inhibitors or monoclonal antibodies.
We have shown a negative correlation between high levels of SIRPB1 and important clinical markers such as WHO grade, IDH status, and 1p/19q co-deletion, which is the first study to investigate SIRPB1's function in the immune milieu of gliomas.Our study, for the first time, investigate SIRPB1's role in glioma's immune microenvironment, and associates high SIRPB1 levels with poor prognosis and key clinical markers, such as WHO grade, IDH status, and 1p/19q co-deletion.Keeping this in mind, and considering Roelands et al. [26,27] and the results that have been published so far, we try to interpret the role of SIRPB1 in gliomas from a variety of angles, such as ICR.We found that in the samples with high ICR, the high expression of SIRPB1 still indicates a poor prognosis.It is also established that SIRPB1 may not "exist" but rather be "involved" in the pathological process of glioma in conjunction with the outcomes of in vitro investigations.We found that SIRPB1 had no prognostic significance when analyzing GBM cohorts alone, and we further analyzed the distribution of SIPRB1 expression in the whole LGG and GBM cohorts.We found that the expression of SIRPB1 in the GBM cohort was generally higher than that in the LGG cohort (Additional file 1: Figure S2B).One possible explanation for no correlation between SIRPB1 and GBM prognosis is that forced subdivision into SIRPB1-HIGH and SIRPB1-LOW in GBM with generally high expression of SIRPB1 will result in insufficient sample size of SIRPB1-LOW to produce sufficient statistical differences.Biological features, immunological microenvironment, and subtype diversity are all more complex in GBM, and while these may be important in predicting prognosis, they are not with simple GBM analysis.

Conclusions
This work established SIRPB1's function in the glioma inhibitory immune milieu.High expression of SIRPB1 is associated with poor prognosis.SYK affects the expression of CCL2, IL1RA, and IL8 and participates in the formation of the glioma immune microenvironment, which is considered to be an independent risk factor for glioma patients.According to our findings, SIRPB1 might be a useful prognostic indicator for gliomas.
group compared to SIRPB1 WT , suggesting SIRPB1 knockout does not affect STAT phosphorylation (Fig.4D, Additional

Fig. 2 A
Fig. 2 A, B SIRPB1 expression in astrocytoma and glioblastoma cell clusters.C Correlation of SIRPB1 with immune cell infiltration.D Association between macrophage infiltration and SIRPB1; Wilcoxon and Spearman tests.E SIRPB1 and macrophage correlation in TCGA-GBM via TIMER2.0.F Kaplan-Meier curves for OS of TCGA-GBMLGG with ICR-high.G Co-localization of SIRPB1 with TMEM119, CD86, and CD163 in glioma.H SIRPB1 levels in glioma and monocyte lines from CCLE.I SIRPB1 expression in human and mouse glioma, microglia, and monocyte lines

Fig. 3
Fig. 3 DEGs (TCGA-GBMLGG) Analysis and Functional Enrichment.A Volcano plot of DEGs in high-vs.low-SIRPB1 samples.B GO and KEGG enrichment terms.C GSEA plots.D PPI network of DEGs.E Key gene modules via MCODE

Fig. 5
Fig. 5 Single-Cell Analysis of IL1RN Expression.A UMAP cell clustering.B IL1RN expression in all cells.C GO and KEGG enrichment for IL1RN.D, E Cell type and pseudotime trajectory of IL1RN in microglia and macrophages.F IL1RN expression dynamics across pseudotime.G, I UMAP dot plots of IL1RN in microglia and macrophages

Table 1
Characteristics and association between SIRPB1 expression and clinicopathologic features of patients with glioma based on TCGA# Shown as median [IQR], Wilcoxon rank sum test CR complete response, PD progressive disease, PR partial response, SD stable disease Fig. 1 A SIRPB1 expression in 33 tumor types vs. controls; Wilcoxon test.B Forest plot of SIRPB1's prognostic value in TCGA tumor types.C Kaplan-Meier curves for OS and PFI.D SIRPB1 levels in normal vs. glioma tissues; Wilcoxon test.E ROC curve for SIRPB1's diagnostic accuracy in gliomas; x-axis: FPR, y-axis: TPR.F Immunohistochemical staining of SIRPB1 in normal and glioma brain tissues and (G) statistical analysis.H Kaplan-Meier curves for OS of glioma patients in First Hospital of Jilin University.I Western blot of SIRPB1 in paracancerous (P) and glioma (T) brain tissues.Significance: ns: P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001 (See figure on next page.)

Table 2
Logistics regression.SIRPB1 expression associated with clinical pathological characteristicsCR complete response, PD progressive disease, PR partial response, SD stable disease

Table 3
Univariate regression and multivariate survival model of prognostic covariates in patients with glioma CR complete response, PD progressive disease, PR partial response, SD stable disease, Mut mutant, WT wildtype